AR053203A1 - Pirazoles y sus derivados - Google Patents

Pirazoles y sus derivados

Info

Publication number
AR053203A1
AR053203A1 ARP060101312A ARP060101312A AR053203A1 AR 053203 A1 AR053203 A1 AR 053203A1 AR P060101312 A ARP060101312 A AR P060101312A AR P060101312 A ARP060101312 A AR P060101312A AR 053203 A1 AR053203 A1 AR 053203A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
hydroxy
phenyl
unsubstituted
Prior art date
Application number
ARP060101312A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR053203A1 publication Critical patent/AR053203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1) en la que uno de R1 y R2 es H o alquilo y el otro es alquilo inferior o (CH2)pY, en el que Y es un anillo cicloalquilo mono-, bi- o tricíclico, saturado, parcialmente insaturado o insaturado, de 5 a 10 eslabones, sustituidos o sin sustituir y p es el numero 0 o 1, y en la que los sustituyentes de Y son alquilo inferior, alcoxi inferior, hidroxi, hidroxi-alquilo, alquil-fenilo, fenil-alquilo, piridina halogeno, o bien R1 y R2, junto con e átomo de N al que están unidos, forman un anillo Sustituido o sin sustituir, en el que Z es un anillo heterocíclico saturado, parcialmente insaturado o insaturado, sustituido o sin sustituir, monocíclico de 5 a 7 eslabones o bicíclico de 7 a 10 eslabones, que contiene el átomo de N al que están unidos R1 y R2, y opcionalmente otro heteroátomo que se elige entre N, O y S, en la que el anillo heterocíclico sustituido está mono- o disustituido por alquilo inferior, hidroxi, hidroxi-alquilo, alquil- fenilo, fenil-alquilo, piridina o halogeno; R3 es un sistema de anillo aromático que se elige entre el grupo formado por [2,2']bitiofenilo, 1-metil-indol, 2,3-dihidro-benzo[1,4]dioxina, benzo[1,3]dioxol, benzo[b]tiofeno, benzotiofeno, dibenzofurano, furano, naftaleno, fenilo, bifenilo, quinolina, tiantreno y tiofeno, en la que dicho anillo aromático puede estar sin sustituir o sustituido por uno o varios grupos amino, cian, formilo, halo, hidroxi, hidroxi-metilo, acilo inferior, acilo inferior- amino, alcoxi inferior, alcoxi inferior-carbonilo, 2-(alcoxi inferior-carbonil)etenilo, alquilo inferior, alquil-tio inferior, nitro, trifluormetoxi o trifluormetilo, dicho anillo fenilo puede estar además sustituido por fenoxi o benciloxi, o R3 es como se muestra en la formula (2) en la que Ar es un grupo arilo carbocíclico o heterocíclico que puede estar sin sustituir o sustituido por uno o varios restos elegidos entre el grupo formad por halogeno, alquilo inferior, alcoxi inferior, trifluormetilo, ciano y nitro; y R4 es alquilo inferior; y las sales farmacéuticamente aceptables del mismo.
ARP060101312A 2005-04-05 2006-04-03 Pirazoles y sus derivados AR053203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66836705P 2005-04-05 2005-04-05

Publications (1)

Publication Number Publication Date
AR053203A1 true AR053203A1 (es) 2007-04-25

Family

ID=36514279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101312A AR053203A1 (es) 2005-04-05 2006-04-03 Pirazoles y sus derivados

Country Status (21)

Country Link
US (1) US7345058B2 (es)
EP (1) EP1928840B1 (es)
JP (1) JP4880671B2 (es)
KR (1) KR100931411B1 (es)
CN (1) CN101155783B (es)
AR (1) AR053203A1 (es)
AT (1) ATE519744T1 (es)
AU (1) AU2006232660B2 (es)
BR (1) BRPI0610459A2 (es)
CA (1) CA2602781C (es)
DK (1) DK1928840T3 (es)
ES (1) ES2369389T3 (es)
IL (1) IL186118A0 (es)
MX (1) MX2007012212A (es)
NO (1) NO20074872L (es)
PL (1) PL1928840T3 (es)
PT (1) PT1928840E (es)
RU (1) RU2381217C2 (es)
TW (1) TWI309645B (es)
WO (1) WO2006106052A1 (es)
ZA (1) ZA200708419B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006316087B2 (en) * 2005-11-21 2011-03-10 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I
HUE026011T2 (en) * 2006-03-22 2016-05-30 Hoffmann La Roche Pyrazoles as 11-beta-HSD-1
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7666888B2 (en) * 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CA2682727C (en) * 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
BRPI0811191A2 (pt) * 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
AU2008277783B2 (en) * 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
FR2924931B1 (fr) * 2007-12-12 2010-01-15 Oreal Utilisations de derives 1-°(1h-pyrazol-4-y!heterocycliques pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute ; nouveaux composes ; compositions les contenant.
WO2009098501A1 (en) * 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
JP2012516327A (ja) * 2009-01-30 2012-07-19 アストラゼネカ アクチボラグ カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法
UY33001A (es) * 2009-11-06 2011-05-31 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
EP2864335A1 (en) 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG Pyranopyridone inhibitors of tankyrase
EP3848027B1 (en) * 2013-11-25 2023-04-05 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
US9273254B2 (en) * 2013-12-20 2016-03-01 Ecolab Usa Inc. Amino acetals and ketals as hydrogen sulfide and mercaptan scavengers
CN103772282B (zh) * 2014-02-26 2015-09-23 上海毕得医药科技有限公司 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
JP2022523376A (ja) 2019-02-22 2022-04-22 コーセプト セラピューティクス， インコーポレイテッド レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
KR20220113767A (ko) 2019-12-11 2022-08-16 코어셉트 쎄라퓨틱스 인코포레이티드 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법
EP4157275A4 (en) * 2020-05-27 2024-06-05 Corcept Therapeutics Inc CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP3A SUBSTRATES
CN114560811B (zh) * 2022-03-11 2023-09-01 上海立森印迹医药技术有限公司 1,3,5-三取代-吡唑-4羧酸衍生物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO760996L (es) * 1975-03-25 1976-09-28 Byk Gulden Lomberg Chem Fab
US4620865A (en) * 1983-11-07 1986-11-04 Eli Lilly And Company Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides
JPH0768220B2 (ja) * 1986-04-24 1995-07-26 三井東圧化学株式会社 新規ピラゾ−ル誘導体、その製造法およびそれらを含有する農園芸用殺菌剤
US4792565A (en) * 1986-04-24 1988-12-20 Mitsui Toatsu Chemicals, Inc. Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds
IL91418A (en) * 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JP2002003410A (ja) 2000-06-27 2002-01-09 Fuji Photo Film Co Ltd 芳香族ハロゲン化物の製造方法。
MXPA03004783A (es) 2000-11-28 2003-09-10 Pfizer Prod Inc Preparacion de inhibidores del intercambiador de sodio-huidrogeno de tipo 1.
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
MXPA04004837A (es) 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
ATE469136T1 (de) 2001-11-22 2010-06-15 Biovitrum Ab Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
AU2002353717B2 (en) 2001-11-22 2006-08-03 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2002337460A1 (en) 2001-12-19 2003-06-30 Pfizer Products Inc. Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
JP4368683B2 (ja) 2002-02-01 2009-11-18 メルク エンド カムパニー インコーポレーテッド 糖尿病、肥満症および脂質代謝異常の治療に有用な１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
EP1482794A1 (en) 2002-03-06 2004-12-08 Merck & Co., Inc. Method of treatment or prevention of obesity
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP2005533858A (ja) 2002-07-27 2005-11-10 アストラゼネカ アクチボラグ 化合物
AU2003269242A1 (en) 2002-10-11 2004-05-04 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
US20060058315A1 (en) 2002-11-07 2006-03-16 Astrazeneca Ab 2-Oxo-ethanesulfonamide derivates
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
DE602004027171D1 (de) * 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
SE0301883D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use II
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
CN1832741A (zh) * 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
US7517900B2 (en) * 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators

Also Published As

Publication number Publication date
CN101155783B (zh) 2012-01-04
MX2007012212A (es) 2007-12-07
EP1928840A1 (en) 2008-06-11
US20060223852A1 (en) 2006-10-05
RU2381217C2 (ru) 2010-02-10
RU2007140737A (ru) 2009-05-20
NO20074872L (no) 2007-10-30
BRPI0610459A2 (pt) 2010-06-22
US7345058B2 (en) 2008-03-18
ATE519744T1 (de) 2011-08-15
TWI309645B (en) 2009-05-11
AU2006232660A1 (en) 2006-10-12
EP1928840B1 (en) 2011-08-10
PL1928840T3 (pl) 2012-01-31
WO2006106052A1 (en) 2006-10-12
AU2006232660B2 (en) 2010-03-25
CA2602781A1 (en) 2006-10-12
ES2369389T3 (es) 2011-11-30
KR20070108937A (ko) 2007-11-13
KR100931411B1 (ko) 2009-12-10
IL186118A0 (en) 2008-01-20
CA2602781C (en) 2011-02-08
CN101155783A (zh) 2008-04-02
JP4880671B2 (ja) 2012-02-22
PT1928840E (pt) 2011-10-03
TW200643013A (en) 2006-12-16
DK1928840T3 (da) 2011-09-12
JP2008534647A (ja) 2008-08-28
ZA200708419B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
AR053203A1 (es) Pirazoles y sus derivados
ECSP088149A (es) 3-acilaminobenzanilidas insecticidas
AR040546A1 (es) Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos
AR055144A1 (es) Inhibidor de secrecion acida
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR048669A1 (es) Derivados biciclicos de bisamida
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
AR071323A1 (es) Derivados heterociclicos de piridazinonas activadores de glucoquinasas, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de la diabetes mellitus tipo ii.
AR060525A1 (es) Piridin [3,4-b] pirazinonas. composiciones farmaceuticas
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
DOP2010000219A (es) Derivados de ftalazinona
AR061867A1 (es) Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa
AR053329A1 (es) Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
ES2334565T3 (es) Agonistas inversos del receptor cb 1.
CO6251264A2 (es) Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k
CR10944A (es) Derivados de espirocromanona sustituida como inhibidores de acc
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
AR062125A1 (es) Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos
CO5700752A2 (es) Derivados de piperazina y piperazin-2-ona especificos al receptor de melano cortina
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
CO5640111A2 (es) Ligandos del receptor cannabinoide y usos de los mismos
AR104121A1 (es) DERIVADOS DE ANILLOS FUSIONADOS DE 9 MIEMBROS CON ACCIÓN SOBRE ACETIL CoA CARBOXILASA
AR057197A1 (es) Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona
AR067665A1 (es) Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
AR056645A1 (es) Compuestos de urea sustituida inhibidores de enzimas chk1 .

Legal Events

Date Code Title Description
FB Suspension of granting procedure